NCT05518643

Brief Summary

The purpose of this study is to evaluate the impact of compliance with enhanced recovery after surgery (ERAS) program on patient reported outcomes (PROs), surgery-specific outcomes and stress response after pancreatic surgery. This prospective observational study will include all consecutive patients undergoing pancreatic surgery over a period of three years (2022 - 2025) at two sites, namely University General Hospital of Larissa and IASO Thessalias, in Greece. Patients will be prospectively enrolled after written informed consent. Data will be collected on patient characteristics, surgical and anaesthetic techniques, complications, and length of stay. Quality of life questionnaires will be administered to patients preoperatively, on the fith postoperative day, first follow-up after discharge, one month and six months after the operation. The stress response will be assessed by measuring the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio (NLR and PLR) preoperatively, and on the first five postoperative days. Data will be collected on pancreatic surgery-specific complications such as delayed gastric emptying (DGE), post-pancreatectomy haemorrhage (PPH) and postoperative pancreatic fistula (POPF) formation. Anonymised data will be uploaded by the principal investigator on a protected excel spreadsheet for analysis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 15, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 21, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 26, 2022

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

April 22, 2025

Status Verified

April 1, 2025

Enrollment Period

2.8 years

First QC Date

August 21, 2022

Last Update Submit

April 16, 2025

Conditions

Keywords

ERASPancreas CancerPROMsStress response to surgerySurgery-ComplicationsPLRNLRQuality of Life

Outcome Measures

Primary Outcomes (5)

  • Change in patient-reported outcomes as measured by the Health Questionnaire EORTC QLQ-C30

    This questionnaire assesses health related quality of life (HRQoL) for cancer patients and includes 30 questions. The QLQ-C30 includes five functional scales (physical, role, emotional, cognitive, and social functioning); eight symptom scales or single items (fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, and diarrhea); an item to assess financial difficulties; 1 global health status scale; and 1 global quality of life scale. Each one of the first 28 items has 4 levels: 1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much. The last 2 questions ask the patient to rate their own health and quality of life on a scale from 1 (very poor) to 7 (excellent). PROMs questionnaires will be distributed in paper format and filled out by pen.

    1 week to 1 day before the operation, postoperative day 5, first follow-up 1 week post discharge, 1 month, and 6 months after the operation

  • Change on the stress response to surgery measured by the Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratio (NLR and PLR).

    NLR and PLR will be calculated by blood tests

    1 week to 1 day before the operation, and postoperative days 1-5

  • Rate of Delayed Gastric Emptying (DGE)

    Number of DGE defined and graded according to the International Study Group of Pancreatic Surgery (ISGPS).

    within 6 weeks from operation

  • Rate of Post Pancreatic Fistula (POPF) formation

    Number of POPF defined and graded according to the International Study Group of Pancreatic Fistula (ISGPF).

    within 6 weeks from operation

  • Rate of Postoperative Pancreatic Haemorrhage (PPH)

    Number of PPH defined and graded according to the International Study Group of Pancreatic Surgery (ISGPS).

    within 6 weeks from operation

Secondary Outcomes (3)

  • Length of hospital stay (LOS)

    within 6 weeks from operation

  • Overall morbidity rate

    Within 3 months from operation

  • Cancer recurrence rate

    within 1 year from operation

Interventions

ERAS protocolPROCEDURE

ERAS protocol as described above

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All consecutive community patients presented for pancreatic surgery

You may qualify if:

  • all pancreatic surgery patients
  • above the age of 18
  • fluent greek speakers
  • without communication barriers

You may not qualify if:

  • younger than 18 years-old
  • unable or unwilling to participate
  • other surgical procedures
  • communication barriers
  • lost to follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Thessaly

Larissa, 45100, Greece

RECRUITING

Related Publications (5)

  • Melloul E, Lassen K, Roulin D, Grass F, Perinel J, Adham M, Wellge EB, Kunzler F, Besselink MG, Asbun H, Scott MJ, Dejong CHC, Vrochides D, Aloia T, Izbicki JR, Demartines N. Guidelines for Perioperative Care for Pancreatoduodenectomy: Enhanced Recovery After Surgery (ERAS) Recommendations 2019. World J Surg. 2020 Jul;44(7):2056-2084. doi: 10.1007/s00268-020-05462-w.

    PMID: 32161987BACKGROUND
  • Spolverato G, Maqsood H, Kim Y, Margonis G, Luo T, Ejaz A, Pawlik TM. Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies. J Surg Oncol. 2015 Jun;111(7):868-74. doi: 10.1002/jso.23900. Epub 2015 Apr 10.

    PMID: 25865111BACKGROUND
  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.

    PMID: 8433390BACKGROUND
  • Bujang MA, Sa'at N, Sidik TMITAB, Joo LC. Sample Size Guidelines for Logistic Regression from Observational Studies with Large Population: Emphasis on the Accuracy Between Statistics and Parameters Based on Real Life Clinical Data. Malays J Med Sci. 2018 Jul;25(4):122-130. doi: 10.21315/mjms2018.25.4.12. Epub 2018 Aug 30.

    PMID: 30914854BACKGROUND
  • Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models. Stat Methods Med Res. 2017 Apr;26(2):796-808. doi: 10.1177/0962280214558972. Epub 2014 Nov 19.

    PMID: 25411322BACKGROUND

MeSH Terms

Conditions

Pancreatic NeoplasmsPancreatic FistulaGastroparesis

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesDigestive System FistulaFistulaPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsStomach DiseasesGastrointestinal DiseasesParalysisNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Despoina Liotiri, Consultant

    University of Thessaly, IASO Thessalias

    PRINCIPAL INVESTIGATOR
  • Dimitrios Zacharoulis, Professor

    University of Thessaly

    STUDY CHAIR
  • Eleni Arnaoutoglou, Professor

    University of Thessaly

    STUDY DIRECTOR

Central Study Contacts

Despoina Liotiri, Consultant

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, DESAIC, PgCert HBE(UK), EDRA, MSc, PhD(c), Consultant Anaesthesiologist

Study Record Dates

First Submitted

August 21, 2022

First Posted

August 26, 2022

Study Start

July 15, 2022

Primary Completion

May 1, 2025

Study Completion

June 1, 2025

Last Updated

April 22, 2025

Record last verified: 2025-04

Locations